Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Two Formulations of Ixekizumab in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ixekizumab

First Posted Date: 2020-02-06

Last Posted Date: 2022-04-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 245

Registration Number: NCT04259346

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States

A Study to Evaluate LY3154207 on the Brain of Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3154207

First Posted Date: 2020-02-06

Last Posted Date: 2022-02-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 16

Registration Number: NCT04258826

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Phase 3

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Tirzepatide
Drug: Dulaglutide

First Posted Date: 2020-02-05

Last Posted Date: 2025-01-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 13299

Registration Number: NCT04255433

Locations: 🇦🇺
GenesisCare, Murdoch, Western Australia, Australia
🇺🇸
Valley Research, Fresno, California, United States
🇺🇸
AMCR Institute, Escondido, California, United States

and more 649 locations

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Lebrikizumab

First Posted Date: 2020-01-31

Last Posted Date: 2023-02-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 206

Registration Number: NCT04250350

Locations: 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
MD Studies, Fountain Valley, California, United States
🇺🇸
Well Pharma Medical Research Corp., Miami, Florida, United States

and more 67 locations

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Biological: Lebrikizumab
Other: Placebo
Other: Topical Corticosteroid

First Posted Date: 2020-01-31

Last Posted Date: 2022-05-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 228

Registration Number: NCT04250337

Locations: 🇺🇸
Center For Dermatology Clinical Research, Inc., Fremont, California, United States
🇺🇸
Wallace Medical Group, Inc., Beverly Hills, California, United States
🇺🇸
GSI Clinical Research, LLC, Margate, Florida, United States

and more 60 locations

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Phase 1

Active, not recruiting

Conditions: Relapsed Solid Tumor
Refractory Solid Tumor

Interventions: Drug: Abemaciclib
Drug: Irinotecan
Drug: Temozolomide
Drug: Dinutuximab
Drug: GM-CSF

First Posted Date: 2020-01-23

Last Posted Date: 2024-06-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 117

Registration Number: NCT04238819

Locations: 🇦🇺
Perth Children's Hospital, Perth, Western Australia, Australia
🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇧🇪
UZ Gent, Gent, Oost-Vlaanderen, Belgium

and more 22 locations

A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2020-01-22

Last Posted Date: 2023-07-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT04235959

Locations: 🇨🇳
Peking University First Hospital, Beijing, China
🇨🇳
West China Hospital Sichuan University, Cheng Du, Sichuan, China

A Study of LY3478006 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: LY3478006 - IV
Drug: Placebo - IV
Drug: LY3478006 - SC
Drug: Placebo - SC

First Posted Date: 2020-01-18

Last Posted Date: 2021-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4

Registration Number: NCT04230122

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Phase 3

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Mirikizumab

First Posted Date: 2020-01-18

Last Posted Date: 2024-10-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 778

Registration Number: NCT04232553

Locations: 🇺🇸
Digestive Health Specialists, Dothan, Alabama, United States
🇺🇸
Research Solutions of Arizona, Litchfield Park, Arizona, United States
🇺🇸
Arizona Arthritis & Rheumatology Associates, Phoenix, Arizona, United States

and more 316 locations

A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: Pegilodecakin

First Posted Date: 2019-12-11

Last Posted Date: 2019-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT04194892

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy